Description
Tirzepatide is a first-in-class dual GIP/GLP-1 receptor agonist that simultaneously activates both incretin pathways for synergistic metabolic effects. By combining GIP-mediated fat oxidation and lipid metabolism with GLP-1-driven appetite suppression and glycemic control, it produces superior outcomes compared to single GLP-1 agonists. In the SURMOUNT-1 Phase 3 trial, Tirzepatide achieved up to 22.5% body weight reduction over 72 weeks, along with significant HbA1c lowering, liver fat reduction, and improvements in cardiovascular risk markers. It is FDA-approved as Mounjaro for type 2 diabetes and Zepbound for obesity. Common side effects are primarily gastrointestinal (nausea, diarrhea, vomiting), mostly mild-to-moderate and transient during dose escalation. Tirzepatide represents a major breakthrough in obesity and metabolic disease treatment. This content is for research purposes only and is provided solely for reference. It must not be interpreted as health, clinical, or legal advice or guidance.
